Insulet (NASDAQ:PODD) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Insulet (NASDAQ:PODD) had its price target hoisted by analysts at Wells Fargo & Company from $144.00 to $172.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 17.40% from the company’s current price.

PODD has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Insulet in a research report on Monday, September 21st. Oppenheimer cut shares of Insulet from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Raymond James Financial restated an “outperform” rating and set a $180.00 price objective on shares of Insulet in a research note on Thursday, August 6th. Citigroup raised their price objective on Insulet from $165.00 to $172.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Insulet in a research report on Wednesday. Twelve investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $185.38.

Insulet Stock Down 6.2%

Shares of Insulet stock traded down $9.61 on Thursday, hitting $146.51. The company had a trading volume of 1,567,721 shares, compared to its average volume of 1,380,594. The firm has a market capitalization of $10.16 billion, a P/E ratio of 23.86, a P/E/G ratio of 1.21 and a beta of 1.06. Insulet has a twelve month low of $126.40 and a twelve month high of $354.88. The stock has a 50-day moving average of $141.97 and a 200-day moving average of $176.65. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.59 by $0.40. The firm had revenue of $842.00 million during the quarter, compared to analysts’ expectations of $832.63 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The company’s revenue was up 19.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.24 EPS. Research analysts predict that Insulet will post 6.75 earnings per share for the current year.

Institutional Trading of Insulet

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Insulet during the 2nd quarter worth about $1,018,582,000. Arrowstreet Capital Limited Partnership lifted its stake in Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after purchasing an additional 1,011,369 shares during the last quarter. Amundi grew its holdings in Insulet by 14.4% during the first quarter. Amundi now owns 446,918 shares of the medical instruments supplier’s stock worth $93,781,000 after purchasing an additional 56,225 shares during the period. Renaissance Technologies LLC grew its holdings in Insulet by 40.5% during the first quarter. Renaissance Technologies LLC now owns 426,003 shares of the medical instruments supplier’s stock worth $89,392,000 after purchasing an additional 122,720 shares during the period. Finally, Man Group plc bought a new position in Insulet during the second quarter worth about $78,746,000.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Several firms raised targets and maintained bullish ratings: RBC lifted its target to $180 and kept an Outperform rating, Bernstein raised its target to $200 and kept Outperform, and Canaccord reiterated Buy with a $179 target. RBC target update Canaccord rating update
• Positive Sentiment: Other analysts also raised targets, while commentary described Insulet as potentially undervalued and highlighted its $1 billion buyback. Recent quarterly results provide support: the company beat earnings and revenue estimates, with revenue up 19.2% year over year, according to the supplied company data. Valuation and buyback article
• Neutral Sentiment: UBS, JPMorgan, Citi, Barclays, Wells Fargo and Leerink all increased their price targets, generally retaining Neutral, Equal Weight or Market Perform ratings. The higher targets are supportive, but the largely unchanged ratings suggest analysts see risks as well as recovery potential.
• Negative Sentiment: Analyst discussion flagged a more conservative 2027 outlook and competition, tempering optimism about Insulet’s growth. Coverage characterized the outlook as moderate despite international strength and an innovation pipeline. RBC outlook article Q3 growth analysis

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.